• Compugen Ltd., of Tel Aviv, Israel, reported findings on the potential of CGEN-15001T, a membrane protein, as a therapeutic target for multiple cancers using monoclonal antibody (mAb) therapy. The results indicated that CGEN-15001T is expressed on numerous types of cancer, including carcinomas, sarcomas, melanoma and hematological cancers, as well as on immune cells.